Holen Sie sich die Stockscreener-App
0.8251
0.47%
-0.012
Atossa Therapeutics Inc Aktie (ATOS) Neueste Nachrichten
Millennium Management LLC Purchases Shares of 29,149 Atossa Therapeutics, Inc. (NASDAQ:ATOS) - Defense World
Atossa Therapeutics, Inc. (NASDAQ:ATOS) Shares Purchased by Two Sigma Advisers LP - Defense World
Ascendiant Capital Markets Issues Positive Forecast for Atossa Therapeutics (NASDAQ:ATOS) Stock Price - Defense World
Craig Hallum Upgrades Atossa Therapeutics (NASDAQ:ATOS) to “Strong-Buy” - Defense World
Atossa Therapeutics (ATOS): Ascendiant Capital Raises Price Targ - GuruFocus
Ascendiant Capital raises Atossa Genetics stock price target to $7.50 By Investing.com - Investing.com India
Ascendiant Capital raises Atossa Genetics stock price target to $7.50 - Investing.com
Craig-Hallum Initiates Coverage of Atossa Therapeutics (BMV:ATOS) with Buy Recommendation - Nasdaq
Craig-Hallum Initiates Coverage of Atossa Therapeutics (ATOS) with Buy Recommendation - Nasdaq
This Excelerate Energy Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - Benzinga
Craig-Hallum Initiates Coverage on Atossa Therapeutics (ATOS) with Buy Rating | ATOS Stock News - GuruFocus
Atossa Therapeutics at Jefferies Conference: Strategic Moves in Breast Cancer - Investing.com Canada
Craig-Hallum initiates Atossa Genetics stock with buy rating By Investing.com - Investing.com UK
Atossa Therapeutics (ATOS) Receives Buy Rating with Promising Ca - GuruFocus
Atossa Therapeutics (ATOS) Receives Buy Rating with Promising Cancer Drug Potential | ATOS Stock News - GuruFocus
Craig Hallum Initiates Coverage on Atossa Therapeutics With Buy Rating, $4 Price Target - MarketScreener
Atossa Therapeutics (ATOS) Receives Positive Coverage and Price Target | ATOS Stock News - GuruFocus
Atossa Therapeutics to Present at the Jefferies Global Healthcare Conference - Bluefield Daily Telegraph
Atossa Therapeutics to Present at the Jefferies Global Healthcare Conference | ATOS Stock News - GuruFocus
Atossa Therapeutics CEO Reveals Latest Breast Cancer Drug Progress at Major Healthcare Conference - Stock Titan
Atossa Therapeutics, Inc. (NASDAQ:ATOS) Shares Acquired by Northern Trust Corp - Defense World
Atossa Therapeutics Reports Q1 2025 Financial Results - TipRanks
Atossa Therapeutics CEO Steven Quay buys $9,886 in common stock - Investing.com Australia
Atossa Therapeutics CEO Steven Quay buys $9,886 in common stock By Investing.com - Investing.com Nigeria
Transcript : Atossa Therapeutics, Inc.Special Call - marketscreener.com
Join Atossa Therapeutics' Exclusive Live Investor Webinar and Q&A Session on May 22 - ACCESS Newswire
Atossa Therapeutics announces issuance of U.S. patent - MSN
Join Atossa Therapeutics' Exclusive Live Investor Webinar and Q&A Session on May 22 | ATOS Stock News - GuruFocus
Atossa CEO to Reveal Latest Phase 2 Results for Next-Gen Breast Cancer Drug in Exclusive Investor Webinar - Stock Titan
HC Wainwright Issues Optimistic Outlook for ATOS Earnings - Defense World
Are Medical Stocks Lagging Atossa Genetics (ATOS) This Year? - Yahoo Finance
Atossa Therapeutics (ATOS) Reports Promising Phase 2 Trial Resul - GuruFocus
Atossa Therapeutics Announces Full Results from I?SPY?2 Endocrin - GuruFocus
Atossa Therapeutics Announces Full Results from I‑SPY 2 Endocrine‑Optimization Sub‑Study Evaluating Low‑Dose (Z)‑Endoxifen - StreetInsider
Wells Fargo & Company MN Has $68,000 Stake in Atossa Therapeutics, Inc. (NASDAQ:ATOS) - Defense World
Phase 2 Trial: New Breast Cancer Drug Achieves 77.7% Tumor Shrinkage with Minimal Side Effects - Stock Titan
Atossa Therapeutics Announces First Quarter 2025 Financial Resul - GuruFocus
Atossa Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Atossa Therapeutics Announces First Quarter 2025 Financial Results and Provides a Corporate Update - goSkagit
ATOSSA THERAPEUTICS, INC. SEC 10-Q Report - TradingView
Atossa Therapeutics Announces First Quarter 2025 Financial Results and Provides a Corporate Update | ATOS Stock News - GuruFocus
Barclays PLC Has $181,000 Holdings in Atossa Therapeutics, Inc. (NASDAQ:ATOS) - Defense World
Atossa Therapeutics (ATOS) to Release Quarterly Earnings on Monday - Defense World
Atossa Therapeutics reports progress in breast cancer treatments - MSN
Atossa Therapeutics and Ainos Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - standard-journal.com
JPMorgan Chase & Co. Buys 211,654 Shares of Atossa Therapeutics, Inc. (NASDAQ:ATOS) - Defense World
ATOS: Atossa Therapeutics Secures New Patent for (Z)-endoxifen F - GuruFocus
ATOS: Atossa Therapeutics Secures New Patent for (Z)-endoxifen Formulations | ATOS Stock News - GuruFocus
A look into Atossa Therapeutics Inc (ATOS)’s deeper side - Sete News
LPL Financial LLC Cuts Stock Position in Atossa Therapeutics, Inc. (NASDAQ:ATOS) - Defense World
0.34%
7.69%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):